AbobotulinumtoxinA + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Compartment Syndrome of Leg
Conditions
Compartment Syndrome of Leg
Trial Timeline
Apr 25, 2024 → Aug 13, 2025
NCT ID
NCT05466539About AbobotulinumtoxinA + Placebo
AbobotulinumtoxinA + Placebo is a approved stage product being developed by Ipsen for Compartment Syndrome of Leg. The current trial status is completed. This product is registered under clinical trial identifier NCT05466539. Target conditions include Compartment Syndrome of Leg.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05466539 | Approved | Completed |
Competing Products
1 competing product in Compartment Syndrome of Leg
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Definity | Lantheus Holdings | Phase 2/3 | 62 |